PT  - JOURNAL ARTICLE
AU  - Rodgers, Florence
AU  - Pepperrell, Toby
AU  - Keestra, Sarai
AU  - Pilkington, Victoria
TI  - Missing clinical trial data: the knowledge gap in the safety of potential COVID-19 drugs
AID  - 10.1101/2020.05.30.20117523
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.30.20117523
4099  - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20117523.short
4100  - http://medrxiv.org/content/early/2020/06/03/2020.05.30.20117523.full
AB  - Objectives Several drugs are being repurposed for the treatment of the coronavirus disease 2019 (COVID-19) pandemic based on in vitro or early clinical findings. As these drugs are being used in varied regimens and dosages, it is important to enable synthesis of existing safety data from clinical trials. However, availability of safety information is limited by a lack of timely reporting of clinical trial results on public registries or through academic publication. We aimed to analyse the knowledge gap in safety data by quantifying the number of missing clinical trial results for drugs potentially being repurposed for COVID-19.Design ClinicalTrials.gov was searched for 19 drugs that have been identified as potential treatments for COVID-19. Relevant clinical trials for any prior indication were listed by identifier (NCT number) and checked for timely result reporting (within 395 days of the primary completion date). Additionally, PubMed and Google Scholar were searched using the NCT number to identify publications of results not listed on the registry. A second, blinded search of 10% of trials was conducted to assess reviewer concordance.Results Of 3754 completed trials, 1516 (40.4%) did not post results on ClinicalTrials.gov or in the academic literature. 1172 (31.2%) completed trials had tabular results on ClinicalTrials.gov. A further 1066 (28.4%) completed trials had results from the literature search, but did not report results on ClinicalTrials.gov. Key drugs missing clinical trial results include hydroxychloroquine (37.0% completed trials unreported), favipiravir (77.8%) and lopinavir (40.5%).Conclusion There is an important evidence gap for the safety of drugs being repurposed for COVID-19. This uncertainty could cause a large burden of additional morbidity and mortality during the pandemic. We recommend caution in experimental drug use for non-severe disease and urge clinical trial sponsors to report missing results retrospectively.Competing Interest StatementSeveral of the co-authors on this paper are part of Universities Allied for Essential Medicines U.K. However, views expressed in this paper are not necessarily that of Universities Allied for Essential Medicines Europe.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is publicly available from the U.S. National Library of Medicine (https://clinicaltrials.gov/ct2/home) https://clinicaltrials.gov/ct2/home